(HealthDay)—Insulin analogs and insulin pen delivery devices remained dominant for ambulatory insulin use for U.S. adults with type 2 diabetes from 2016 to 2020, according to a study published online Oct. 12 in JAMA Network ...
Oct 18, 2021
0
2
Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.
Jun 11, 2012
0
0
(HealthDay)—Neither glargine followed by metformin nor metformin alone halts the progressive deterioration of β-cell function in youth with impaired glucose tolerance (IGT) or recently-diagnosed type 2 diabetes, according ...
Jul 13, 2018
0
0
(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...
May 26, 2015
0
3
(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...
Aug 6, 2013
0
0
(HealthDay)—In a case report published online May 1 in Diabetes Care, resolution of hypoglycemia and cardiovascular dysfunction after rituximab treatment of insulin autoimmune syndrome is described.
May 7, 2017
0
0
For patients with diabetes, bringing down and maintaining lower blood glucose levels is important to minimize the risk of long-term complications such as nerve damage, kidney damage, an increased risk of heart disease, eye ...
Jun 10, 2019
0
4
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...
Jan 13, 2013
0
0
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia— low blood sugar— compared with the commercially available insulin glargine, a new meta-analysis study ...
Jun 18, 2013
0
0
(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...
Oct 25, 2012
0
0
